On May 22, Taiwan Bio Therapeutics announced that its cell therapy manufacturing plant has passed inspection by Taiwan's Ministry of Health and Welfare's Food and Drug Administration (TFDA), obtaining PIC/S GMP certification for its pilot plant. This milestone makes Taiwan Bio Therapeutics the first domestic pharmaceutical company to pass GMP inspection for allogeneic mesenchymal stem cell new drugs.
The inspected product, which received GMP certification at the Phase II clinical trial stage, demonstrates that Taiwan Bio Therapeutics's mass production capabilities meet global regulatory standards and quality requirements for commercial production. This achievement showcases Taiwan Bio Therapeutics's manufacturing strength, accelerating the advancement of new drug clinical trials and enhancing international client trust. It is expected to significantly boost orders from the US and other international CDMO markets, positively impacting overall operations.
Taiwan Bio Therapeutics noted that with the imminent passage of the US Biosecurity Act, CDMO companies linked to China will gradually withdraw from the world's largest US pharmaceutical market. This development creates over a billion-dollar opportunity in the cell therapy CDMO supply chain. Taiwan Bio Therapeutics has been strategically positioning itself in the US market for years and has established preliminary recognition. With the new GMP certification, Taiwan Bio Therapeutics is well-placed to capitalize on the US cell therapy CDMO market, leveraging its advanced testing and process development capabilities to fill the gap in early-stage cell therapy manufacturing.
The PIC/S GMP certification covers the allogeneic bone marrow mesenchymal stem cell product, Chondrochymal, which is indicated for the treatment of degenerative arthritis. Having completed patient enrollment for its Phase II clinical trial, the company is currently analyzing the data and plans to apply for Phase III clinical trial (IND) approval from the TFDA.
Chief Operating Officer Chun-Yao Yang emphasized that Taiwan Bio Therapeutics is one of the few global CDMO companies focusing on early-stage, high-end cell therapy products. The company ensures seamless integration from technology transfer, process development to mass production through its robust R&D capabilities, unique development model, and comprehensive GMP system, offering a one-stop complete solution.
Furthermore, Taiwan Bio Therapeutics stands out for its close collaboration with hospitals, ensuring the entire process from tissue collection to cell infusion into patients is meticulously managed to guarantee product quality and maximize patient benefits. The company has formed a strategic alliance with Taichung Veterans General Hospital and is in talks with leading US medical institutions for similar collaborations, directly reaching potential new cell therapy drug clients and accelerating business development in the US market.
Currently, Taiwan Bio Therapeutics's revenue is primarily driven by its CDMO business. Cumulative revenue for the first four months of this year reached NT$17.73 million, marking an 83.14% year-on-year increase and setting a historical high for the same period. This figure surpasses the total revenue of NT$12.39 million for the first half of last year. The recent TFDA inspection approval further enhances Taiwan Bio Therapeutics's visibility and competitiveness in the international market, aiding its efforts to seize the burgeoning cell therapy CDMO market opportunities.
Resource (mandarin):
